CHEMM ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.…
Industry Peers
Medical DevicesKey Statistics
About ChemoMetec (CPH: CHEMM)
›
ChemoMetec (CPH: CHEMM) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 174 employees.
The shares were at 702.50 DKK on 19 November 2026, down 4.4% over 52 weeks. Its 52-week range is 235.20 DKK to 796.50 DKK: the price is 11.8% below the high and 198.7% above the low.
At a market capitalisation of 12.06B DKK, it trades at 60.6 times trailing earnings and 39.2 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 136% for CHEMM.
ChemoMetec reports return on equity of 27.8%, an operating margin of 49.1% and revenue up 7.4% year over year.
It holds more cash than debt, a net cash position of 288.97M DKK. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 780.00 DKK is 11.0% above the current price. The next earnings report is expected on 2 February 2027.